Sign in
Taking people in FrancePhase 3

Tests hydrochlorothiazide in adults with polycystic kidney disease

Compares hydrochlorothiazide with placebo in adults with polycystic kidney disease.

Key facts

Who runs it
University Medical Center Groningen
Where
Bordeaux, Brest, Lyon Cedex 03, Paris, and Vandoeuvre Les Nancy, FranceSee the 5 sitesAlso in 6 other countries, 20 sites
Registry title
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Status
Recruiting
Phase
Phase 3
People taking part
300 people, planned
Started
31 Jul 2024
Expected to end
Jul 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hydrochlorothiazide 25 mg
  • Placebo
Record updated
25 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with autosomal dominant polycystic kidney disease (ADPKD) who already take a V2RA drug such as tolvaptan. It tests whether adding hydrochlorothiazide helps.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
ADPKD diagnosed by the modified Ravine criteria, with eGFR above 25 mL/min/1.73m2.
Earlier treatment
Must be on stable treatment with the highest tolerated dose of V2RA for at least 3 months. Must not use any diuretic.

Main reasons for not taking part

  • Known intolerance to hydrochlorothiazide
  • Use of any diuretic
  • Low blood pressure (below 105/65mmHg) or dizziness on standing
  • Uncontrolled high blood pressure (above 160/100mmHg)
  • Low potassium (below 3.5 mmol/L)

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • ADPKD diagnosis (modified Ravine criteria)
  • ≥18 years old
  • eGFR > 25 mL/min/1.73m2
  • On stable treatment with the highest tolerated dose of V2RA for a minimum of 3 months

Who cannot take part

  • Uncontrolled hypertension (blood pressure >160/100mmHg)
  • History of active gout on maintenance preventive treatment for gout (allopurinol, desuric and/or colchicine), defined as ≥2 episodes during the last year
  • History of skin cancer (basal cell, squamous cell and melanoma)
  • Hypokalemia (<3.5 mmol/L)
  • Known intolerance to hydrochlorothiazide
  • Use of any diuretic
  • Orthostatic hypotension complaints or blood pressure <105/65mmHg during screening visit

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in France

Also in 6 other countries, 20 sites

  • Pellegrin HospitalBordeaux, FranceTaking people
  • Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
  • Hospital Edouard HerriotLyon Cedex 03, FranceTaking people
  • Hopital Necker Enfants MaladesParis, FranceTaking people
  • CHRU De NancyVandoeuvre Les Nancy, FranceTaking people

About the trial

What the trial wants to find out

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive formation of renal cysts which ultimately lead to a loss of renal function.

Read full original descriptionShow less

Tolvaptan (a V2R antagonist) is currently the only effective treatment for preserving renal function in ADPKD. However, side-effects such as polyuria limit its tolerability and thereby the therapeutic potential. This study will test whether co-administration with hydochlorothiazide can improve V2RA efficacy (slowing kidney function decline) and tolerability (quality of life) in ADPKD. Approximately 300 patients will be enrolled.

The 2 groups in the trial

  • HydrochlorothiazideExisting treatment, for comparison

    Oral hydrochlorothiazide 25mg, once daily, for a total of 156 weeks

    Treatment: Hydrochlorothiazide 25 mg

  • PlaceboPlacebo, for comparison

    Matching oral placebo, once daily, for a total of 156 weeks. The placebo is inert.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
Plain-language title
Tests hydrochlorothiazide in adults with polycystic kidney diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05373264, who can take part
Record updated
25 August 2026